Lenz & Staehelin with Vivalto Partners on Linnea acquisition

Lenz & Staehelin advised Vivalto Partners on Swiss tax matters in connection with its acquisition of Linnea, an international pharmaceutical manufacturer of botanical ingredients based in Switzerland.

The context

Headquartered in Paris, Vivalto Partners is an independent management company, specialised in investments across the healthcare sector.

Following the transaction, the French company acquired 100% of Swiss pharmaceutical manufacturer Linnea. The selling part is a specialist in the production of both botanical extracts and isolates as well semi-synthetic APIs derived from botanicals.

This transaction takes the form of a primary buyout, with a substantial investment from Linnea’s management team,  aiming to support its development in the field of plant-based therapeutics and botanical ingredients.

The Lenz & Staehelin team

Partner Daniel Schafer (pictured) led the Lenz & Staehelin team on the matter, working alongside associate Marine Ecabert (both tax).